1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The ADDF-Harrington Scholar Program identifies and accelerates promising drug discovery research for Alzheimer's disease and related dementias, with explicit support for AI/ML-enabled approaches including generative AI for novel drug candidate identification, deep learning for target validation, AI-driven repurposing of approved drugs, and computational platforms for amyloid and tau pathology.
Scholars receive a 2-year grant of $600K plus comprehensive drug development expertise from the Harrington Discovery Institute and ADDF's Drug Development Accelerator. Optional follow-on investment through ADDF's venture arm. Strong fit for academic investigators with promising preclinical leads, AI-enabled drug discovery platforms, or novel computational therapeutic approaches.
Get alerted about grants like this
Save a search for “Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Faculty-level investigators at academic institutions, research nonprofits, and academic medical centers worldwide. Must have novel drug discovery research with clear translational pathway. Industry-only applications not eligible but industry partnerships welcomed. Confirm the full requirements in the official notice before applying.
The current listing shows USD 600,000 over 2 years per scholar plus comprehensive drug development support valued at additional USD 700,000-1,000,000. Total package approximately USD 1,300,000-1,600,000 per awardee. Up to 5 scholars selected per cycle. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias are due August 15, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias is funded by Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleDARPA and NSF launched a joint program on June 1 to fund university work on AI interpretability, control, and adversarial robustness. Awards run $750K to $3M+ per project, the forum launches this summer, and the universities listed in the AI Forge repository will sit closest to the money. The Request for Information closes June 22.
Read articleOn June 1, 2026, DARPA and the National Science Foundation announced AI Forge — a jointly governed forum that will fund, guide, and manage university-led research on AI interpretability, AI control, and adversarial robustness. The RFI on sam.gov closes June 22. The forum itself will be administered by a new nonprofit launching in summer 2026. The structure is what matters: this is not a one-off solicitation, it is a multi-year venue for university-government-industry research that operates outside the normal merit-review timelines of either agency. What university research teams should be doing in the seventeen-day window between the announcement and the RFI deadline — and what the forum model means for federal AI funding through FY 2028.
Read article